Zealand Pharma A/S (ZEAL.CO)
- Previous Close
599.00 - Open
601.00 - Bid 619.00 x --
- Ask 620.00 x --
- Day's Range
598.50 - 621.50 - 52 Week Range
212.20 - 749.00 - Volume
135,097 - Avg. Volume
417,847 - Market Cap (intraday)
38.608B - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-12.46 - Earnings Date May 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
789.25
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
www.zealandpharma.comRecent News: ZEAL.CO
Performance Overview: ZEAL.CO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZEAL.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZEAL.CO
Valuation Measures
Market Cap
37.30B
Enterprise Value
35.79B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
98.88
Price/Book (mrq)
23.42
Enterprise Value/Revenue
104.40
Enterprise Value/EBITDA
-54.31
Financial Highlights
Profitability and Income Statement
Profit Margin
-205.30%
Return on Assets (ttm)
-19.93%
Return on Equity (ttm)
-58.43%
Revenue (ttm)
342.79M
Net Income Avi to Common (ttm)
-703.74M
Diluted EPS (ttm)
-12.46
Balance Sheet and Cash Flow
Total Cash (mrq)
1.63B
Total Debt/Equity (mrq)
7.49%
Levered Free Cash Flow (ttm)
-228.98M
Research Analysis: ZEAL.CO
Company Insights: ZEAL.CO
ZEAL.CO does not have Company Insights